---
slug: semaglutide-statins
title: "semaglutide statins"
kind: standard
status: published
hash: 3efdf4cf5b9f41016ffb8527fcb810c4e7f687c4a9b05146a3d66fe32e5120ce
created: 2026-06-29T18:00:25.616Z
updated: 2026-10-08T11:49:26.664Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# semaglutide statins

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T18:01:05.441Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/) — “Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.” (sha256 1f72eb3ab262a943)
2. [Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab](https://pubmed.ncbi.nlm.nih.gov/40866272/) — “We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.” (sha256 8dac09512937ff88)
3. [Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles](https://pubmed.ncbi.nlm.nih.gov/40284475/) — “The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.” (sha256 fee791885efc2754)
4. [Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy](https://pubmed.ncbi.nlm.nih.gov/40166440/) — “Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.” (sha256 1f72eb3ab262a943)
5. [Cardiovascular benefits of semaglutide: a systematic review and meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/) — “This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...” (sha256 0a91029a9c981cbd)
6. [Cardiovascular outcomes of semaglutide and tirzepatide for ...](https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/) — “Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...” (sha256 72faf83af984751f)